Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE) have received a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $18.00.

A number of research firms have recently weighed in on MSLE. Leerink Partners began coverage on Satellos Bioscience in a research note on Monday, April 6th. They set an “outperform” rating and a $20.00 price target for the company. Cantor Fitzgerald initiated coverage on Satellos Bioscience in a research note on Wednesday, March 11th. They issued an “overweight” rating on the stock. Wall Street Zen raised Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Satellos Bioscience in a research note on Monday, May 18th. Finally, Canaccord Genuity Group raised Satellos Bioscience to a “moderate buy” rating in a research note on Thursday, May 21st.

Satellos Bioscience Price Performance

MSLE opened at $5.71 on Friday. Satellos Bioscience has a fifty-two week low of $4.54 and a fifty-two week high of $13.39. The business’s 50-day moving average price is $6.93. The stock has a market cap of $118.94 million, a P/E ratio of -3.57 and a beta of 1.54.

Satellos Bioscience (NASDAQ:MSLE) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). Equities analysts forecast that Satellos Bioscience will post -1.69 earnings per share for the current year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.